phosphodiesterase 4
Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases
... inhibitors have been developed, their introduction in the clinic has been hampered by their narrow therapeutic window with side effects such as nausea and emesis occurring at sub-therapeutic levels. The latest generation ...
15
Rolipram, a Phosphodiesterase 4 Inhibitor, Stimulates Inducible cAMP Early Repressor Expression in Osteoblasts
... 17. Miyamoto K, Waki Y, Horita T, Kasugai S, Ohya K. Reduction of bone loss by denbufylline, an inhibitor of phosphodiesterase 4. Biochem Pharmacol 1997;54:613-7. 18. Wong BR, Rho J, Arron J, Robinson E, ...
6
Targeting phosphodiesterase 4 as a potential therapeutic strategy for enhancing neuroplasticity following ischemic stroke
... Sensorimotor recovery following ischemic stroke is highly related with structural modification and functional reorganization of residual brain tissues. Manipulations, such as treatment with small molecules, have been ...
10
The effect of resveratrol on beta amyloid-induced memory impairment involves inhibition of phosphodiesterase-4 related signaling
... by phosphodiesterase (PDE) activities, the further study found that resveratrol is a PDE ...of phosphodiesterase 4 (PDE 4) inhibitors in learning and memory performance has provoked intense ...
13
Phosphodiesterase 4-targeted treatments for autoimmune diseases
... active phosphodiesterase 4 and tumor necrosis factor- α ...1, 4- cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of ...
8
Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD
... selective phosphodiesterase 4 inhibitor, for the “maintenance treatment of severe chronic obstructive pulmonary disease (COPD, FEV 1 postbronchodilator less than 50% predicted) associated with chronic ...
12
Dimerization of cAMP phosphodiesterase-4 (PDE4) in living cells requires interfaces located in both the UCR1 and catalytic unit domains
... a 4-helix bundle in dimeric PDE4 long forms (vide infra), such that hydrophobic surfaces running along the proposed helices are a major contributory feature to a dimerization ...
14
Roflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patients
... In 2010, roflumilast, a selective PDE-4 inhibitor with anti-inflammatory properties, was approved by the European Medicines Agency for use as once-daily oral maintenance treatment for adult patients with severe or ...
6
Leucine-rich repeat kinase 2 controls protein kinase A activation state through phosphodiesterase 4
... Here, by assessing LRRK2-PKA RIIβ interaction and RIIβ phos- phorylation state, we found that LRRK2 G2019S interacts more with RIIβ compared to the WT protein in cells and brain lysates [r] ...
11
Additive anti-inflammatory effects of corticosteroids and phosphodiesterase-4 inhibitors in COPD CD8 cells
... Fig. 3 The effect of GSK256066 with dexamethasone on cytokine release from pulmonary CD8 cells. Pulmonary CD8 cells from COPD ( n = 6) and smokers with normal lung function ( n = 4) were pre-treated with various ...
11
The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma
... Reducing FeNO levels by specific iNOS inhibition does not inhibit the EAR or LAR, suggesting that nitric oxide is not mechanistically involved in the pathophysiology of allergen-induced asthma [17]. However, FeNO is a ...
10
Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors
... We have previously reported on the stably transduced PKA, Epac 1 and Epac 2 knockdown Raw 264.7 cells and shown that there was a marked reduction in the expression of these proteins [19]. Briefly, Raw 264.7 cells (15,000 ...
13
The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma
... The LAR is characterised by an inflammatory cell influx into the airways, comprising a variety of cell types including eosinophils, basophils and lymphocytes that are recruited by T-helper 2 (TH2) cytokines [25]. The LAR ...
9
Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice
... To find if general suppression of inflammatory cells release was also reflected in lung inflammatory cytokines expression, expression of TNF-α, IL-1β and IL-6 was ana- lyzed at the same time points as the cell count ...
9
Emerging treatment options for psoriasis
... phosphodiesterase 4, is under development for the treat- ment of psoriatic arthritis, psoriasis, ankylosing spondyli- tis, Behçet’s syndrome, atopic dermatitis, and rheumatoid ...
9
Apremilast for the treatment of active psoriatic arthritis: a single-centre real-life experience
... oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE ...
9
Management of patients during and after exacerbations of chronic obstructive pulmonary disease: the role of primary care physicians
... and phosphodiesterase-4 inhibitor) that represent maintenance pharmacotherapies to prevent future exacerbations, as well as management of coexisting nonpul- monary conditions and strategies to optimize ...
12
IN-SILICO APPROACH FOR THE IDENTIFICATION OF NEW MOLECULES FOR ALZHEIMER’S DISEASE (AD)
... Alzheimer’s disease (AD) is a malignant neurodegenerative disorder which causes the destruction of brain cells that ultimately results in memory loss and cognitive dysfunction. Deposition of b-amyloid fibril, the ...
16
Expression studies of recombinant cAMP-specific phosphodiesterase type 4
... About a decade ago, Liljestrom and Garoff, 1991 developed a m amm alian expression system based on Semliki Forest Virus (SPY). This system since its development has been used to express a large number o f recombinant ...
242
Recent Developments in Atopic Dermatitis
... selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): a phase-II randomized, double-blind, placebo-controlled ...
14